Clinical trials work by comparing predefined interventions and outcomes in carefully selected groups of human participants according to a research protocol. Researchers first define a question, establish eligibility criteria, determine the intervention and comparator, choose outcomes and calculate an appropriate study size. Participants are then recruited and followed according to the protocol. Depending on the trial, participants may be randomised to different groups and may or may not know which intervention they receive. Researchers collect outcome and safety data and use statistical analysis to estimate the treatment effect and its uncertainty. The objective is to determine whether observed differences are plausibly attributable to the intervention rather than to chance, bias or other explanations.
Recruitment begins with eligibility criteria. Inclusion criteria identify characteristics required for participation, while exclusion criteria identify circumstances that could create unacceptable risk or make the results difficult to interpret. Criteria can include age, diagnosis, disease severity, previous treatment, laboratory values, pregnancy status and other factors. Researchers need enough participants to answer the question with adequate statistical power, but recruiting too many participants can expose unnecessary people to research risks and resources. A representative participant population also matters because a trial's findings may not generalise well to people who were excluded or underrepresented.
Once participants enrol, allocation to study groups can occur through randomisation. Randomisation uses chance to assign participants and, when adequately implemented, helps balance known and unknown confounding factors between groups. Stratified or blocked randomisation can be used to maintain balance for important characteristics or throughout recruitment. Some trials are single-arm studies and therefore do not have a randomised comparator, while others may have two or more treatment groups. The design is chosen according to the scientific question and ethical circumstances.
The comparator can be a placebo, standard treatment, another experimental treatment, no intervention or another appropriate control condition. Placebo controls are useful when withholding active treatment is ethically acceptable. Active-control trials are especially important when an established effective therapy exists and the question concerns whether the new intervention is better, similarly effective with advantages in safety or convenience, or otherwise preferable. The comparator determines what clinical question the trial actually answers, so a drug that beats placebo does not necessarily outperform current standard treatment.
Trials collect predefined outcome data. A primary outcome is the main result used to answer the principal research question, while secondary outcomes address additional questions. Outcomes may include mortality, disease events, symptom scores, functional measures, quality of life, laboratory markers or adverse events. Researchers distinguish statistical significance from clinical importance: a small difference can be statistically detectable in a very large study but have little practical value, while an important effect can fail to reach conventional statistical significance in a small underpowered study. Confidence intervals provide information about the precision of effect estimates.
Blinding can reduce bias. If participants know they received the new treatment, expectations may affect subjective symptoms or behaviour. If clinicians know allocations, they may unconsciously treat groups differently or assess outcomes differently. In a double-blind design, relevant participants and research personnel are kept unaware of allocation where feasible. Some interventions cannot be blinded, so researchers use other safeguards such as objective outcomes, standardised procedures and blinded outcome assessors. NIH describes masking as a method for reducing the influence of treatment knowledge on research results.
Safety monitoring continues throughout the study. Researchers record adverse events, serious adverse events, laboratory abnormalities and other potential harms. Independent monitoring may review accumulating data and can recommend modifications or stopping when continuing would be unsafe or when there is compelling evidence of benefit or harm. The balance between benefits and harms is central because an intervention that improves one outcome but produces serious adverse effects may not provide an overall clinical advantage. Regulatory and ethical requirements govern the conduct and reporting of trials.
After data collection, researchers analyse outcomes according to the prespecified statistical plan. They estimate differences between groups, calculate measures such as risk ratios, odds ratios or hazard ratios when appropriate, and report confidence intervals and uncertainty. Results are then interpreted in light of the study design, population, adherence, missing data, adverse events, statistical limitations and applicability to other patients. A single trial rarely provides the complete answer to a medical question. Its findings are incorporated with other trials, observational evidence, systematic reviews, biological knowledge and patient preferences to inform clinical decisions.
